Navigation Links
The Expected Approval of Velcade Will Be a Significant Driver of Growth in the Graft Versus Host Disease Drug Market
Date:2/7/2013

BURLINGTON, Mass., Feb. 7, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the expected supplemental approval of Millennium (Takeda)/Johnson & Johnson's Velcade for the treatment of chronic graft versus host disease (GVHD) will be a significant driver of growth in the GVHD market through 2021. In particular, Velcade's uptake in the first-line treatment setting will displace lower-priced standards of care such as corticosteroids and small-molecule immunosuppressants.

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36784LOGO )

According to Niche Markets and Rare Diseases: Graft Versus Host Disease, expert physicians report that Velcade's market potential could be even greater, based on their interest in employing Velcade in the prophylactic setting. The market opportunity for prophylactic therapies, based on underlying population sizes, is up to three times larger than for primary or later-line treatments.

The report also finds that although the current clinical pipeline is sparse, several drug developers have nevertheless been drawn into GVHD drug development by the potential to secure orphan-drug designation for novel agents.

"GVHD is an excellent illustration of the orphan drug designation working effectively -- without the benefits of the orphan designation, companies might be reluctant to develop drugs for such a small, specific population," said Decision Resources Senior Vice President Cynthia Mundy , Ph.D.

GVHD is a relatively rare condition that occurs in a patient population -- severely ill oncology patients eligible for hematopoietic stem cell transplant -- who already have access to costly specialized treatment. Interviewed hematologist/oncologists report that cost concerns have little to no impact on current treatment decisions, and do not anticipate major changes in payers' attitudes toward GVHD reimbursement following launches of novel therapies.

About Graft Versus Host Disease
Graft Versus Host Disease is offered as part of Decision Resources' Niche Markets and Rare Diseases service. Each report assesses opportunity in a select drug market across the United States, France, Germany, Italy, Spain and the United Kingdom. The report provides detailed coverage of patient populations, current therapies, unmet needs and emerging therapies, and includes primary research with country-specific thought leaders.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
2. French Lifestyle Secret Finally Revealed: Lycotec Publishes Unexpected Findings on Roquefort Cheese
3. Global Bioinformatics Market is Expected to Reach USD 9.1 Billion in 2018: Transparency Market Research
4. Global Ostomy Drainage Bags Market is Expected to Reach USD 2.6 Billion in 2018: Transparency Market Research
5. Global High Potency Active Pharmaceutical Ingredients (HPAPIs) Market is Expected to Reach USD 17.5 billion in 2018: Transparency Market Research
6. Global Neuromodulation Devices Market is Expected to Reach USD 7,072.6 Million in 2018: Transparency Market Research
7. Global ECG Monitoring Systems Market is Expected to Reach USD 822.1 Million in 2016: Transparency Market Research
8. Global Insulin Market Expected to Reach USD 32,346.7 Million in 2018, with China Alone Accounting for 10.2%: Transparency Market Research
9. U.S. Vaccine Market is Expected to Reach USD 17.4 Billion by 2018: Transparency Market Research
10. Global Laparoscopy Devices Market is Expected to Reach USD 13,152.9 Million in 2018: Transparency Market Research
11. Orexigen Therapeutics announces continued rapid enrollment into the Light Study; enrollment now expected to close by year end 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016 Amgen (NASDAQ: ... Annual Global Healthcare Conference at 9:15 a.m. ET on ... . David W. Meline , executive vice president ... conference. Live audio of the presentation can be accessed from ... Investors. A replay of the webcast will also be available ...
(Date:2/5/2016)... -- Redwood Scientific Technologies, Inc. announced today the development and ... balance their hormones. This product will be featuring Redwood,s ... Cardiff , President and CEO. "I am proud that ... of women across the country and around the world ... research and development team is confident that through the ...
(Date:2/5/2016)...  Syneron Medical Ltd. (NASDAQ: ELOS ), ... that William Griffing , Chief Executive Officer ... participate in the Leerink Partners 5 th ... in New York City . ... with the Mr. Griffing and will include a ...
Breaking Medicine Technology:
(Date:2/5/2016)... ... February 05, 2016 , ... Love is in the air at ... of colors, assortments and packaging. This staple for Valentine’s Day is a must-have, and ... , For Valentine’s Day, not only are long-stem roses available, but also other flower ...
(Date:2/5/2016)... (PRWEB) , ... February 05, 2016 , ... ... the availability of the company's lighter, sleeker next generation LYNX VR Indoor Trainer ... , Improvements in design and manufacturing not only reduce the weight of ...
(Date:2/5/2016)... ... February 05, 2016 , ... Today, the Whole-Food Warrior ... that the much-anticipated feature with author Jahnavi Foster, specialist in healthy vegetarian cuisine, will ... , Each week, on his weekly Whole-Food Warrior TV show, Frank Davis highlights Whole-Food ...
(Date:2/5/2016)... ... 2016 , ... Successful recruitment and retention efforts, new collaborations ... have all marked the last 12 months at Roswell Park Cancer Institute (RPCI). ... oldest cancer center, Candace S. Johnson, PhD, outlined the many accomplishments of her ...
(Date:2/5/2016)... ... February 05, 2016 , ... The event is being held on April ... in Minneapolis, Minn. Triumph Over Parkinson’s will fund nearly $100,000 for research for the ... lives with Parkinson’s disease and is the architect of this informative event to raise ...
Breaking Medicine News(10 mins):